Breaking News Instant updates and real-time market news.

AAPL

Apple

$148.98

-6.01 (-3.88%)

, GE

General Electric

$28.95

1.01 (3.61%)

12:12
06/12/17
06/12
12:12
06/12/17
12:12

On The Fly: Top stock stories at midday

Stocks opened in the red and have moved in negative territory throughout the morning, extending its losses from Friday. The Nasdaq has been the drag again as a number of big name, large cap tech stocks continue to pullback from their recent highs amid rotation into other sectors. Oil prices have managed to hold onto their gains, rising nearly 1.5% near noon to sit firmly above $46 per barrel. ECONOMIC EVENTS: In the U.S., the VIX, a measure of equity volatility, hit a one month high of 12.37 before settling back below 12 in morning trading as the rotation from tech high-fliers into other underperforming sectors persisted into a second straight session. COMPANY NEWS: Shares of Apple (AAPL), which fell nearly 4% on Friday, have declined another 2.5% today after Mizuho analyst Abhey Lamba downgraded the stock to Neutral and lowered his price target for the shares to $150 from $160 saying "enthusiasm" around the upcoming iPhone launch is fully priced in after the stock's year-to-date outperformance... Meanwhile, a nearly 4% advance in General Electric (GE) is buoying the Dow. The blue chip conglomerate is rising after longtime CEO Jeff Immelt announced plans to retire at year end. John Flannery, the current President and CEO of GE Healthcare, has been named CEO of the company effective August 1, and Chairman and CEO effective January 1, 2018. MAJOR MOVERS: Among the notable gainers was QIWI (QIWI), which gained 3.5% after shareholder Otkritie said it intends to make a cash tender offer, at a price of $28 per share, for up to nearly 25M outstanding Class B ordinary shares. Among the noteworthy losers was Coherus Biosciences (CHRS), which dropped 27% after the FDA issued a complete response letter for its biosimilar version of Amgen's (AMGN) Neulasta. Also lower were shares of STMicroelectronics (STM), which was among the many underperforming names in the semiconductor sector. Near noon, the stock was down 6%. The Fly's technical analyst noted earlier that the stock is now below what was an important support at the $16 area. INDEXES: Near midday, the Dow was down 73.83, or 0.35%, to 21,198.14, the Nasdaq was down 49.28, or 0.79%, to 6,158.63, and the S&P 500 was down 8.62, or 0.35%, to 2,423.15.

AAPL

Apple

$148.98

-6.01 (-3.88%)

GE

General Electric

$28.95

1.01 (3.61%)

CHRS

Coherus Biosciences

$20.65

-2.05 (-9.03%)

AMGN

Amgen

$164.06

1.41 (0.87%)

QIWI

QIWI

$23.53

0.02 (0.09%)

STM

STMicroelectronics

$15.47

-1.0738 (-6.49%)

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 15

    Jun

  • 20

    Jun

  • 22

    Jun

  • 19

    Jul

  • 14

    Aug

  • 02

    Oct

AAPL Apple
$148.98

-6.01 (-3.88%)

06/07/17
RBCM
06/07/17
NO CHANGE
RBCM
Analog Devices weakness will be short lived, says RBC Capital
RBC Capital analyst Amit Daryanani notes that Analog Devices (ADI) "has underperformed rather notably" since its Q2 results on May 31. The analyst blames the weakness on the company's reduced revenue from Apple (AAPL). However, he thinks that investors will begin focusing more on the company's multiple tailwinds, possibly starting in the wake of its June 20 Analyst Day. Consequently, he expects the stock to rise from current levels and keeps a $92 price target and Outperform rating on the shares.
06/11/17
MZHO
06/11/17
DOWNGRADE
Target $150
MZHO
Neutral
Apple downgraded to Neutral from Buy at Mizuho
Mizuho analyst Abhey Lamba downgraded Apple to Neutral from Buy and lowered his price target for the shares to $150 from $160. The iPhone maker fell along with the Nasdaq index late in Friday's trade to close down 4%, or $6.01, to $148.98. "Enthusiasm" around the upcoming iPhone launch is fully priced in after the stock's year-to-date outperformance, Lamba wrote to investors Sunday night. The analyst sees limited upside to consensus estimates and notes Apple shares are trading near the upper-end of their recent valuation range.
06/12/17
BERN
06/12/17
NO CHANGE
BERN
Apple slowdown in China probably a temporary pause, says Bernstein
Bernstein analyst A.M. (Toni) Sacconaghi, Jr. says that weakening sales of Apple's iPhone in China is probably due to a temporary pause in demand ahead of the company's new iPhone scheduled to debut later this year, rather than a result of competition from other high-end devices. The analyst continues to believe that Apple's risk/reward ratio is attractive and keeps a $160 price target and Outperform rating on the stock.
06/07/17
ARGS
06/07/17
NO CHANGE
ARGS
Apple price target raised to $175 from $160 at Argus
Argus analyst Jim Kelleher increased his price target on Apple after the company annoucned new products and product enhancements. The analyst quotes Apple bears as saying that the company is "playing catch-up" by introducing similar products to those that its rivals have already launched. However, Kelleher says that, "coming late to the party did not hurt iPhone's leadership in smartphones." He keeps a Buy rating on the shares. .
GE General Electric
$28.95

1.01 (3.61%)

06/01/17
FBCO
06/01/17
NO CHANGE
Target $34
FBCO
Outperform
General Electric has reached attractive entry point, says Credit Suisse
Credit Suisse analyst Julian Mitchell thinks the pendulum of investor sentiment regarding General Electric has swung too far in the negative direction, creating an attractive entry point into the stock. GE's organic growth seems underappreciated, argues Mitchell, who notes that its organic sales growth has topped most Electrical Equipment and Multi-Industry peers in recent years and into 2017. Meanwhile, GE's segments have shown "fairly healthy" operating leverage, added Mitchell, who has an Outperform rating and $34 price target on GE shares.
05/31/17
DBAB
05/31/17
NO CHANGE
Target $24
DBAB
Sell
General Electric setting stage for dividend cut, says Deutsche Bank
Deutsche Bank analyst John Inch believes the stage is being set for General Electric to cut its common dividend. The analyst has a Sell rating on the shares with a $24 price target. Last Wednesday at a conference, GE provided a cash flow walk for the next two years that suggests it is likely to generate insufficient free cash flow to cover its common dividend this year, and barely enough next year, Inch tells investors in a research note. He believes a "reasonable dividend payout" on a future earnings reset could result in a GE dividend cut to 65c-75c. A dividend reduction could be part of an earnings "reset" lower and possibly in conjunction with eventual future leadership change, Inch writes.
05/25/17
DBAB
05/25/17
NO CHANGE
Target $24
DBAB
Sell
GE officially walked away from 2018 EPS target, says Deutsche Bank
Deutsche Bank analyst John Inch says General Electric CEO Jeff Immelt at a conference yesterday officially walked away from the company's $2.00-plus earnings per share framework for 2018 citing tougher markets. While investors had expected GE to abandon the $2.00-plus target, the company kept $2.00 per share at the high end of its 2018 framework, Inch tells investors in a research note. He believes $2.00 to be unrealistic, even as just a high point in the range. The analyst sees cash flow pressures continuing in 2018 and keeps a Sell rating on GE with a $24 price target.
05/12/17
05/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sell from Hold at Deutsche Bank with analyst John Inch saying the stock is overvalued given "weak earnings quality" and the "wide gap between non-cash and cash earnings." 2. Electronic Arts (EA) was downgraded to Neutral from Long-Term Buy at Hilliard Lyons and to Sell from Hold at Deutsche Bank. 3. Uni-Pixel (UNXL) downgraded to Neutral from Buy at Roth Capital with analyst Brian Alger saying while he sees abundant industry demand and interest for the company's products, he sees Uni-Pixel's future as somewhat binary and dependent upon strategic partnerships being executed relatively quickly. Alger also lowered his price target on the shares to 45c from $2. 4. Akari Therapeutics (AKTX) downgraded to Market Perform from Outperform at William Blair with analyst Tim Lugo citing the company's announcement that it placed its Chief Executive Officer on administrative leave as it reviews any involvement with the Edison Report. 5. Mazor Robotics (MZOR) downgraded to Market Perform from Outperform at JMP Securities with analyst David Turkaly citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CHRS Coherus Biosciences
$20.65

-2.05 (-9.03%)

06/12/17
BMOC
06/12/17
NO CHANGE
Target $43
BMOC
Outperform
Coherus Biosciences weakness a buying opportunity, says BMO Capital
BMO Capital analyst Ian Somaiya said CHS-1701 CRL is disappointing but the issues raised are addressable, and expects a timely resolution and re-submission. The analyst lowered Coherus Biosciences' price target to $43 from $54, assuming a one-year delay in the US and reduced probability of an on-time European approval, but said to use weakness as a buying opportunity and maintains an Outperform rating.
06/12/17
FBCO
06/12/17
NO CHANGE
Target $38
FBCO
Outperform
Credit Suisse 'cautiously optimistic' on timelines laid out by Coherus
Credit Suisse analyst Alethia Young reiterates her previous belief that shares of Coherus Biosciences could trade to $12-$15 based on a complete response letter scenario. The CRL news today is not worst case, however, as there were not major issues like running wrong clinical studies, manufacturing and fill-finish, Young tells investors in a research note. The analyst believes approval of CHS-1701 remains the catalyst for Coherus. This means the key catalyst is likely shifted until mid or second half of 2018. Young writes. The analyst is "cautiously optimistic" on the timelines laid out by management and keeps an Outperform rating on the shares. The stock in morning trading is down 27% to $15.07.
06/12/17
STPT
06/12/17
NO CHANGE
STPT
Buy
Coherus Biosciences selloff an overreaction, says Standpoint Research
Standpoint Research analyst Ronnie Moas views this morning's selloff in shares of Coherus Biosciences as an overreaction. The analyst maintains a Buy rating on the name but pushed out his $40 price target to 2019 from 2018 following the company's complete response letter from the FDA. The FDA has "merely requested" additional information, which Coherus can provide, Moas tells investors in an email after listening to the company's conference call. The stock in premarket trading is down 30%, or $6.26, to $14.39.
AMGN Amgen
$164.06

1.41 (0.87%)

05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/22/17
FBCO
05/22/17
NO CHANGE
Target $177
FBCO
Neutral
Amgen romosozumab U.S. approval in July 'off the table,' says Credit Suisse
After Amgen (AMGN) and UCB (UCBJY) announced that the Evenity "ARCH" study met both primary endpoints but that there was also a newly observed cardiovascular safety signal in the trial, Credit Suisse analyst Alethia Young said any potential U.S. approval by the drug's July 19 PDUFA date is "off the table" and it is unclear as of now what U.S. approval timelines may be. She reduced her probability of success for romosozumab to 80% from 100% and lowered her price target on Amgen to $177 from $178. Young keeps a Neutral rating on Amgen shares.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
QIWI QIWI
$23.53

0.02 (0.09%)

01/18/17
JPMS
01/18/17
NO CHANGE
JPMS
QIWI's Sberbank revenue could be at risk, says JPMorgan
JPMorgan said Alibaba's (BABA) AliExpress is int talks with Sberbank over a joint-venture in Russia. The firm's analyst estimates 20% of QIWI's (QIWI) ecommerce revenue is generated from physical e-commerce, about 6% of total revenue, and AliExpress is responsible for a majority of that generated revenue. A joint-venture would mean all the payment processing would likely go through Sberbank's own platform, the firm's analyst believes.
04/10/17
JPMS
04/10/17
UPGRADE
Target $23
JPMS
Overweight
QIWI upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alexei Gogolev upgraded QIWI to Overweight saying the company is "finally turning the corner" after six quarters of single-digit sales growth. The improving macro environment and consumer sentiment are likely to boost core business operations, the analyst contends. Gogolev raised his price target for the shares to $23 from $15.
STM STMicroelectronics
$15.47

-1.0738 (-6.49%)

03/30/17
CHLM
03/30/17
NO CHANGE
CHLM
Samsung S8 launch positive for STMicroelectronics, others, says Craig-Hallum
Craig-Hallum analyst Tony Stoss notes that Samsung (SSNLF) Galaxy S8's features were as he had expected, which is positive for STMicroelectronics (STM), Cypress Semiconductor (CY) and Integrated Device Synaptics (IDTI), and largely a non-impact for Synaptics (SYNA). The analyst says Samsung using USB-C for the port should be a benefit for Cypress as it is the likely supplier of USB-C controllers for the phone. Additionally, Samsung has enabled the S8 for wireless fast charging and showcased a fast charge wireless pad, which is likely an ASP increase from previous wireless charging solutions Integrated Device Synaptics was providing. The phone also features a fingerprint sensor on the back that is likely Synaptics, he notes, adding that this should be roughly in-line with previous ASP's of fingerprint sensors that the latter has provided to Samsung.
04/05/17
CHLM
04/05/17
NO CHANGE
Target $18
CHLM
Buy
STMicroelectronics to benefit from content jump in iPhone 8, says Craig-Hallum
Craig-Hallum analyst Anthony Stoss raised his STMicroelectronics' (STM) March and June quarter estimates to account for content increases in Samsung's (SSNLF) Galaxy S8 and Apple's (AAPL) iPhone 8, coupled with continued strong demand for the Nintendo (NTDOY) Switch and strength in the company's connected car business. The analyst says STMicroelectronics remains one of his top names in 2017 and would be a buyer heading into both the S8 and iPhone 8 launches. He reiterates a Buy rating and $18 price target on STMicroelectronics' shares.
05/15/17
STFL
05/15/17
DOWNGRADE
STFL
Hold
STMicroelectronics downgraded to Hold from Buy at Stifel
05/15/17
05/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Adam Jonas saying the bull thesis on Tesla centers around the company becoming the next Amazon (AMZN) or Apple (AAPL), Jonas tells investors in a research note. The analyst, however, questions if the risks of taking on the tech giants is sufficiently discounted in the share price. He expects "much larger and more well capitalized" competitors to unveil strategies that directly address sustainable transport and mobility. 2. J.C. Penney (JCP) was downgraded to Hold from Buy at Deutsche Bank, to Neutral from Outperform at Baird, and to Neutral from Buy at Buckingham. 3. STMicroelectronics (STM) downgraded to Hold from Buy at Stifel. 4. Level 3 (LVLT) and CenturyLink (CTL) were downgraded to Underperform from Market Perform at Raymond James. 5. TSMC (TSM) downgraded to Neutral from Outperform at Credit Suisse with analyst Randy Abrams saying headwinds from excess inventory, slower China smartphones, and Qualcomm (QCOM) shifts to Samsung (SSNLF) could pressure sales and margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BABA

Alibaba

$185.13

-0.3 (-0.16%)

18:01
11/19/17
11/19
18:01
11/19/17
18:01
Hot Stocks
Alibaba, Auchan Retail, Ruentex form new retail strategic alliance »

Alibaba, Auchan Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, CMCSA

Comcast

$36.16

-0.91 (-2.45%)

17:32
11/19/17
11/19
17:32
11/19/17
17:32
Hot Stocks
Box Office Battle: 'Justice League' wins weekend with just $96M »

Warner Bros.' (TWX)…

TWX

Time Warner

$88.72

0.71 (0.81%)

CMCSA

Comcast

$36.16

-0.91 (-2.45%)

CMCSK

Comcast

SNE

Sony

$46.17

0.07 (0.15%)

FOX

21st Century Fox

$30.48

1.88 (6.57%)

FOXA

21st Century Fox

$31.15

1.83 (6.24%)

LGF.A

Lionsgate

$32.59

1.55 (4.99%)

DIS

Disney

$103.44

-0.16 (-0.15%)

VIAB

Viacom

$26.15

2.46 (10.38%)

VIA

Viacom

$33.00

2.9 (9.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

17:10
11/19/17
11/19
17:10
11/19/17
17:10
Periodicals
GE yet to decide which directors will lose seats, WSJ reports »

A housecleaning at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$90.83

-0.66 (-0.72%)

17:01
11/19/17
11/19
17:01
11/19/17
17:01
Hot Stocks
Galapagos NV reports positive topline results from ALBATROSS with GLPG2222 »

Galapagos NV reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$262.26

-1.44 (-0.55%)

16:55
11/19/17
11/19
16:55
11/19/17
16:55
Hot Stocks
Boeing, Avolon finalize deal for 75 737 MAX airplanes »

Boeing and Avolon have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBLK

Star Bulk Carriers

$9.60

0.19 (2.02%)

16:53
11/19/17
11/19
16:53
11/19/17
16:53
Earnings
Star Bulk Carriers reports Q3 adjusted EPS (8c), consensus (5c) »

"We released today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

BDRBF

Bombardier

$2.43

0.0007 (0.03%)

16:22
11/19/17
11/19
16:22
11/19/17
16:22
Hot Stocks
Bombardier predicts Latin America's 60-150 seat aircraft fleet will double »

Bombardier Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TSLA

Tesla

$315.05

2.55 (0.82%)

10:21
11/18/17
11/18
10:21
11/18/17
10:21
Periodicals
Tesla new super car to cost $200,000, Recode says »

Alongside its new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 16

    Jan

GT

Goodyear Tire

$29.94

0.63 (2.15%)

10:17
11/18/17
11/18
10:17
11/18/17
10:17
Hot Stocks
Goodyear Tire, NASCAR extend relationship »

NASCAR and Goodyear Tire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Jan

  • 16

    Jan

HMC

Honda

$32.62

0.02 (0.06%)

10:05
11/18/17
11/18
10:05
11/18/17
10:05
Periodicals
Honda recalls 900,000 minivans on tip forward seats, Reuters says »

Honda Motor is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.43

-0.82 (-0.92%)

09:48
11/18/17
11/18
09:48
11/18/17
09:48
Periodicals
Activist investors Nelson Peltz still in P&G picture, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

09:39
11/18/17
11/18
09:39
11/18/17
09:39
Periodicals
Buy Baker Hughes, Barron's says »

While it is "not…

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

GE

General Electric

$18.21

-0.04 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CSCO

Cisco

$35.90

0.02 (0.06%)

09:19
11/18/17
11/18
09:19
11/18/17
09:19
Periodicals
More needed for Cisco to have 'groove back,' Barron's says »

While the Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.